BostonSight Reveals Five-Year Strategic Road Map to Advance Lens Technology

Published on February 18, 2026
NEEDHAM, Mass.—BostonSight announced it has developed a transformative five-year strategic roadmap aimed at redefining ocular surface treatment through groundbreaking advancements in clinical research, education, and specialty lens technology. BostonSight stated that it has designated key leadership roles to head initiatives that accelerate innovation and collaboration, with the goal of positively impacting patient lives around the world. Karen Carrasquillo, OD, Ph.D., FAAO, FSLS, FBCLA, BostonSight’s chief innovation and education officer, and Andrew Heim, chief technology officer, will spearhead BostonSight’s innovation and technology strategy.
Continue reading on website
Other news

Opus Genetics Enters Agreement for $25 Million Private Placement

February 18, 2026
RESEARCH TRIANGLE PARK, N.C.—Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced that it has entered into a securities purchase agreement (SPA) for a private placement of 7,374,632 shares of its Series B non-voting convertible preferred stock at

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

February 18, 2026
LONDON and NEW YORK—OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, has announced the pricing of an underwritten public offering of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The company said it granted the unde